Danatlas

DanAtlas is a biopharmaceutical company based in Beijing, China, focused on the research, development, and commercialization of drug candidates targeting oncology, inflammation, hematological conditions, and metabolic disorders. The company develops a range of therapeutic products, including both small molecules and biologics, and maintains a pipeline that includes first-in-class and globally innovative compounds.

With an internal research and development team and collaborations across the pharmaceutical sector, DanAtlas advances its drug candidates through preclinical and clinical stages. Its portfolio includes treatments for solid tumors, blood cancers, autoimmune diseases, and metabolic syndromes, with several programs in various stages of clinical evaluation.

DanAtlas works to meet international standards for drug development and regulatory compliance, aiming to serve both domestic and global markets. The company combines in-house innovation with external partnerships to support the development and potential commercialization of its therapies.

Keywords: DanAtlas, Beijing Danqing Pharmaceutical, biopharmaceutical, drug development, oncology, inflammation, hematology, metabolic disease, clinical trials, small molecule, biologics, pharmaceutical R&D, China biotech, innovative therapeutics.